Pfizer (NYSE:PFE) Trading Down 2.7% – Here’s Why

Pfizer Inc. (NYSE:PFE)’s stock price fell 2.7% on Wednesday . The stock traded as low as $23.93 and last traded at $24.05. 75,014,186 shares traded hands during trading, an increase of 78% from the average session volume of 42,113,230 shares. The stock had previously closed at $24.72.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Ibrance for frontline maintenance use in advanced breast cancer, giving Pfizer a modest commercial win and supporting revenue for an established oncology drug.
• Positive Sentiment: Pfizer declared its third-quarter 2026 dividend of $0.43 per share, reinforcing its appeal as a high-yield income stock and signaling confidence in cash flow.
• Positive Sentiment: Some recent analysis says a bullish case still makes sense despite the patent cliff, suggesting the stock may be attractive on valuation and dividend support.
• Neutral Sentiment: Pfizer has drawn increased trader attention, with Zacks noting that PFE is a trending stock as investors reassess its prospects.
• Neutral Sentiment: Pfizer Ventures helped lead a $62 million Series B for Oblenio Bio, a capital deployment that could create longer-term strategic optionality but is not likely to move the stock materially right away.
• Negative Sentiment: Pfizer halted a tafamidis bioequivalence study, which adds uncertainty around a potential formulation/clinical program and may be viewed as a setback for pipeline execution. Pfizer Halts Tafamidis Bioequivalence Study
• Negative Sentiment: Recent lung cancer trial disappointment in sigvotatug vedotin continues to weigh on sentiment, reinforcing fears that Pfizer may struggle to replace revenue lost to patent expirations.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on PFE shares. HSBC increased their target price on shares of Pfizer from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, April 9th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a report on Monday, March 2nd. Morgan Stanley upped their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Finally, CICC Research assumed coverage on Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Price Performance

The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The company has a market capitalization of $138.35 billion, a PE ratio of 18.43 and a beta of 0.34. The company’s 50-day simple moving average is $26.00 and its 200-day simple moving average is $26.30.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the prior year, the company earned $0.92 earnings per share. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Institutional Investors Weigh In On Pfizer

Hedge funds have recently modified their holdings of the stock. Vermillion Wealth Management Inc. boosted its holdings in shares of Pfizer by 19.4% in the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after acquiring an additional 382 shares in the last quarter. Triad Wealth Partners LLC boosted its holdings in Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares in the last quarter. Eagle Capital Management LLC raised its stake in shares of Pfizer by 0.3% during the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after buying an additional 390 shares in the last quarter. ETF Store Inc. boosted its stake in shares of Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares in the last quarter. Finally, Delta Financial Advisors LLC boosted its stake in shares of Pfizer by 1.6% in the first quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after buying an additional 398 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.